Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alberta Is Second Canadian Province To Switch To Biosimilars

Follows British Columbia Switching Program That Began This Year

Executive Summary

Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

You may also be interested in...



What’s Next? Five Things To Look Out For In May

This month, Eli Lilly’s Alimta blockbuster will lose patent protection in the US, while Teva – which will also publish its Q1 financial results – will see Bristol Myers Squibb begin its appeal process against a key UK ruling involving the originator’s Eliquis (apixaban) anticoagulant.

Alberta Expands Biosimilar Switching With Adalimumab

Alberta has become the latest Canadian province to expand its biosimilar switching program to cover adalimumab biosimilars to Humira.

Third Canadian Province Follows On Biosimilar Switching

New Brunswick has become the latest Canadian province to introduce a biosimilar switching program, with the newly-introduced scheme covering several biologic molecules.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel